Close Menu

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Friday recommended approval for GlaxoSmithKline's anti-PD-1 antibody dostarlimab for patients with mismatch repair deficient (dMMR) and microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.